[1]
|
McGlynn, K.A., Petrick, J.L. and El-Serag, H.B. (2021) Epidemiology of Hepatocellular Carcinoma. Hepatology, 73, 4-13. https://doi.org/10.1002/hep.31288
|
[2]
|
Chidambaranathan-Reghupaty, S., Fisher, P.B. and Sarkar, D. (2021) Hepatocellular Carcinoma (HCC). Epidemiology, Etiology and Molecular Classification. Advances in Cancer Research, 149, 1-61.
https://doi.org/10.1016/bs.acr.2020.10.001
|
[3]
|
Forner, A., Reig, M. and Bruix, J. (2021) Hepatocellular Carcinoma. The Lancet, 391, 1301-1314.
https://doi.org/10.1016/S0140-6736(18)30010-2
|
[4]
|
Le Grazie, M., Biagini, M.R., Tarocchi, M., Polvani, S. and Galli, A. (2017) Chemotherapy for Hepatocellular Carcinoma. The Present and the Future. World Journal of Hepatology, 9, 907-920. https://doi.org/10.4254/wjh.v9.i21.907
|
[5]
|
Rizell, M., Sternby Eilard, M., Andersson, M., Andersson, B., Karlsson-Parra, A. and Suenaert, P. (2019) Phase 1 Trial with the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma. Frontiers in Oncology, 9, Article No. 19. https://doi.org/10.3389/fonc.2019.00019
|
[6]
|
Bruix, J., Chan, S.L., Galle, P.R., Rimassa, L. and Sangro, B. (2021) Systemic Treatment of Hepatocellular Carcinoma. An EASL Position Paper. Journal of Hepatology, 75, 960-974. https://doi.org/10.1016/j.jhep.2021.07.004
|
[7]
|
Cheng, A.L., Hsu, C., Chan, S.L., Choo, S.P. and Kudo, M. (2020) Challenges of Combination Therapy with Immune Checkpoint Inhibitors for Hepatocellular Carcinoma. Journal of Hepatology, 72, 307-319.
https://doi.org/10.1016/j.jhep.2019.09.025
|
[8]
|
Kudo, M., Ueshima, K., Yokosuka, O., Ogasawara, S., Obi, S., Izumi, N., et al. (2018) Sorafenib Plus Low-Dose Cisplatin and Fluorouracil Hepatic Arterial Infusion Chemotherapy versus Sorafenib alone in Patients with Advanced Hepatocellular Carcinoma (SILIUS): A Randomised, Open Label, Phase 3 Trial. The Lancet Gastroenterology & Hepatology, 3, 424-432. https://doi.org/10.1016/S2468-1253(18)30078-5
|
[9]
|
Swann, J.B. and Smyth, M.J. (2007) Immune Surveillance of Tumors. Journal of Clinical Investigation, 117, 1137-1146. https://doi.org/10.1172/JCI31405
|
[10]
|
Shlomai, A., de Jong, Y.P. and Rice, C.M. (2014) Virus Associated Malignancies. The Role of Viral Hepatitis in Hepatocellular Carcinoma. Seminars in Cancer Biology, 26, 78-88. https://doi.org/10.1016/j.semcancer.2014.01.004
|
[11]
|
Hato, T., Goyal, L., Greten, T.F., Duda, D.G. and Zhu, A.X. (2014) Immune Checkpoint Blockade in Hepatocellular Carcinoma. Current Progress and Future Directions. Hepatology, 60, 1776-1782. https://doi.org/10.1002/hep.27246
|
[12]
|
Ruf, B., Heinrich, B. and Greten, T.F. (2021) Immunobiology and Immunotherapy of HCC. Spotlight on Innate and Innate-Like Immune Cells. Cellular & Molecular Immunology, 18, 112-127.
https://doi.org/10.1038/s41423-020-00572-w
|
[13]
|
Lu, C., Rong, D., Zhang, B., Zheng, W., Wang, X., Chen, Z., et al. (2019) Current Perspectives on the Immunosuppressive Tumor Microenvironment in Hepatocellular Carcinoma: Challenges and Opportunities. Molecular Cancer, 18, Article No. 130. https://doi.org/10.1186/s12943-019-1047-6
|
[14]
|
Shen, Y.C., Hsu, C.L., Jeng, Y.M., Ho, M.C., Ho, C.M., Yeh, C.P., et al. (2020) Reliability of a Single-Region Sample to Evaluate Tumor Immune Microenvironment in Hepatocellular Carcinoma. Journal of Hepatology, 72, 489-497.
https://doi.org/10.1016/j.jhep.2019.09.032
|
[15]
|
Kim, E. and Viatour, P. (2020) Hepatocellular Carcinoma: Old Friends and New Tricks. Experimental & Molecular Medicine, 52, 1898-1907. https://doi.org/10.1038/s12276-020-00527-1
|
[16]
|
Zhai, Y., Moosavi, R. and Chen, M. (2021) Immune Checkpoints, a Novel Class of Therapeutic Targets for Autoimmune Diseases. Frontiers in Immunology, 12, Article ID: 645699. https://doi.org/10.3389/fimmu.2021.645699
|
[17]
|
Pisibon, C., Ouertani, A., Bertolotto, C., Ballotti, R. and Cheli, Y. (2021) Immune Checkpoints in Cancers: From Signaling to the Clinic. Cancers, 13, Article No. 4573. https://doi.org/10.3390/cancers13184573
|
[18]
|
Jacquelot, N., Ghaedi, M., Warner, K., Chung, D.C., Crome, S.Q. and Ohashi, P.S. (2021) Immune Checkpoints and Innate Lymphoid Cells-New Avenues for Cancer Immunotherapy. Cancers, 13, Article No. 5967.
https://doi.org/10.3390/cancers13235967
|
[19]
|
Jansson, A., Barnes, E., Klenerman, P., Harlén, M., Sørensen, P., Davis, S.J., et al. (2005) A Theoretical Framework for Quantitative Analysis of the Molecular Basis of Costimulation. The Journal of Immunology, 175, 1575-1585.
https://doi.org/10.4049/jimmunol.175.3.1575
|
[20]
|
Zou, W., Wolchok, J.D. and Chen, L. (2016) PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response Biomarkers, and Combinations. Science Translational Medicine, 8, 328rv4.
https://doi.org/10.1126/scitranslmed.aad7118
|
[21]
|
Zhou, Q., Xiao, H., Liu, Y., Peng, Y., Hong, Y., Yagita, H., et al. (2010) Blockade of Programmed Death-1 Pathway Rescues the Effector Function of Tumor-Infiltrating T Cells and Enhances the Antitumor Efficacy of Lentivector Immunization. The Journal of Immunology, 185, 5082-5092. https://doi.org/10.4049/jimmunol.1001821
|
[22]
|
Anderson, A.C., Joller, N. and Kuchroo, V.K. (2016) Lag-3, Tim-3, and TIGIT: Co-Inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity, 44, 989-1004. https://doi.org/10.1016/j.immuni.2016.05.001
|
[23]
|
Toor, S.M., Sasidharan Nair, V., Decock, J. and Elkord, E. (2020) Immune Checkpoints in the Tumor Microenvironment. Seminars in Cancer Biology, 65, 1-12. https://doi.org/10.1016/j.semcancer.2019.06.021
|
[24]
|
Crocenzi, T., Meyer, T., Melero, I., Yau, T., Hsu, C., Kudo, M., et al. (2018) Tu1483-Hepatic Safety and Biomarker Assessments in Sorafenib experienced Patients with Advanced Hepatocellular Carcinoma Treated with Nivolumab in the Checkmate-040 Study. Gastroenterology, 154, S-1234. https://doi.org/10.1016/S0016-5085(18)34061-7
|
[25]
|
El-Khoueiry, A.B., Sangro, B., Yau, T., Crocenzi, T.S., Kudo, M., Hsu, C., et al. (2017) Nivolumab in Patients with Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase 1/2 Dose Escalation and Expansion Trial. The Lancet, 389, 2492-2502. https://doi.org/10.1016/S0140-6736(17)31046-2
|
[26]
|
Adcock, C.S., Puneky, L.V. and Campbell, G.S. (2019) Favorable Response of Metastatic Hepatocellular Carcinoma to Treatment with Trans-Arterial Radioembolization Followed by Sorafenib and Nivolumab. Cureus, 11, e4083.
https://doi.org/10.7759/cureus.4083
|
[27]
|
Zhu, A.X., Finn, R.S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., et al. (2018) Pembrolizumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib (KEYNOTE-224): A Non-Randomised, Open-Label Phase 2 Trial. The Lancet Oncology, 19, 940-952. https://doi.org/10.1016/S1470-2045(18)30351-6
|
[28]
|
Finn, R.S., Ryoo, B.Y., Merle, P., Kudo, M., Bouattour, M., Lim, H.Y., et al. (2020) Pembrolizumab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. Journal of Clinical Oncology, 38, 193-202. https://doi.org/10.1200/JCO.19.01307
|
[29]
|
Lee, H.T., Lee, J.Y., Lim, H., Lee, S.H., Moon, Y.J., Pyo, H.J., et al. (2017) Molecular Mechanism of PD-1/PD-L1 Blockade via Anti-PD-L1 Antibodies Atezolizumab and Durvalumab. Scientific Reports, 7, Article No. 5532.
https://doi.org/10.1038/s41598-017-06002-8
|
[30]
|
Tan, S., Liu, K., Chai, Y., Zhang, C.W., Gao, S., Gao, G.F., et al. (2018) Distinct PD-L1 Binding Characteristics of Therapeutic Monoclonal Antibody Durvalumab. Protein & Cell, 9, 135-139.
https://doi.org/10.1007/s13238-017-0412-8
|
[31]
|
Kelley, R.K., Sangro, B., Harris, W., Ikeda, M., Okusaka, T., Kang, Y.K., et al. (2021) Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients with Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. Journal of Clinical Oncology, 39, 2991-3001.
https://doi.org/10.1200/JCO.20.03555
|